A phase 2 trial of bevacizumab, iparomlimab and tuvonralimab and nab-paclitaxel in triple-negative breast cancer, run by Fudan University, now recruiting.
QL1706 Plus Chemotherapy +/- Bevacizumab in 1L Treatment of R/mTNBC is a phase 2, interventional study registered as NCT06786026 by Fudan University, with a registry enrolment figure of 60 participants, started 2024-10-09 and due to reach its primary completion in 2025-09-30. Interventions recorded: bevacizumab; QL1706; Nab paclitaxel. Conditions listed: TNBC, Triple Negative Breast Cancer. Sites: China. No results are recorded here; the registry entry is the source.
Shares Nab-paclitaxel, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Nab-paclitaxel, Bevacizumab, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Nab-paclitaxel, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Nab-paclitaxel, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Nab-paclitaxel, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Nab-paclitaxel, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Nab-paclitaxel, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Iparomlimab and tuvonralimab, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.